Macquarie says Mesoblast's MSB's acquisition of Osiris's cultured stem-cell assets is a worrying sign for the industry

Tom McKay

Macquarie says Mesoblast's MSB's acquisition of Osiris's cultured stem-cell assets is a worrying sign for the industry. Whilst this transaction appears to offer little downside for MSB, they are concerned that a insider and pioneer is seemingly giving up on the industry. The low transaction price suggests both a low internal value placed on stem-cell therapies, and little interest from external parties.


Tom McKay

I'm the Managing Director and Co-Founder of Livewire. I'm passionate about collecting and curating the markets most informed insights every day so that our members can discover new investment ideas. If you would like to get in touch - please use...

Expertise

stem cells biotech

Comments

Please sign in to comment on this wire.